Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring–Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6
Authors' conclusion
In adults with type 1 diabetes, estimated rate ratios for CGM-based clinically significant hypoglycemia were lower than those estimated from SMBG data, although still favoring degludec with estimated rate ratios of 1.28-1.38. CGM metrics varied by treatment day after icodec injection, but median duration of CGM-based hypoglycemia was comparable between treatment arms.
Study context
- Population
- Adults with T1D
- Comparison
- Once-weekly insulin icodec vs once-daily insulin degludec
Methodological detailsopen continuous glucose monitoring (CGM)
- Open CGM
Primary result
As reported in the abstract
Estimated rate ratio (CGM)
1.38
baseline to week 26; Self-measured blood glucose (SMBG)-based rate ratio 1.88
Estimated rate ratio (CGM)
1.28
baseline to week 57; SMBG-based rate ratio 1.79
Further findings
Median duration of CGM-based hypoglycaemic episodes (<3.9 mmol/L) · baseline to week 26
Median duration of CGM-based hypoglycaemic episodes (<3.9 mmol/L) · baseline to week 57
Median duration of CGM-based periods <3.0 mmol/L · week 26 and week 57
Time in range (TIR), time above range (TAR), time below range (TBR) by treatment day after icodec injection · weeks 0-4, 22-26 and 48-52
- TIR highest on days 2-4 after icodec injection, with concomitant reduction in TAR and increase in TBR
Median duration of CGM-based hypoglycaemic episodes (<3.9 mmol/L) · baseline to week 26
- Comparable between treatment arms
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →